Drug Research

The pharmaceutical sector is currently witnessing a profound shift in the methodology used to identify new chemical and biological entities. For decades, the discovery process relied heavily on high-throughput screening, where millions of existing molecules were tested against a...

The pharmaceutical industry is currently facing a critical challenge in the management of safety risks associated with new drug candidates. For decades, the high rate of attrition during late-stage clinical trials has been a primary driver of the rising...

The pharmaceutical industry is currently facing a period of intense structural adjustment as the costs associated with bringing a new therapy to market continue to rise. For decades, the industry has operated under a model where the average cost...

The pharmaceutical industry has long struggled with the immense complexity of conditions affecting the central nervous system. For decades, the high failure rate in clinical trials for Alzheimer's and Parkinson's disease has been a source of frustration for researchers...

The global oncology sector is currently undergoing a significant shift as the complexity of the disease continues to outpace traditional research methods. For decades, the search for effective treatments was defined by a broad approach that often failed to...

The pharmaceutical sector is currently witnessing a fundamental shift in how orphan drugs are identified and moved through the clinical pipeline. For decades, the primary challenge for researchers has been the sheer scarcity of patient data and the immense...

The emergence of chimeric antigen receptor T cell therapy has been one of the most significant breakthroughs in the history of hematology oncology. By re engineering a patient’s own immune cells to recognize and attack cancer, researchers have achieved...